Chinese Journal of Integrative Medicine, Год журнала: 2024, Номер unknown
Опубликована: Дек. 2, 2024
Язык: Английский
Basic Research in Cardiology, Год журнала: 2024, Номер unknown
Опубликована: Июль 17, 2024
Abstract Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of immune system against malignant cells. However, their use is associated with a spectrum adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to toxicity ICIs. First, dysregulation checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) its ligand (PD-L1), molecular mimicry cardiac autoantigens, leads immune-related events, myocarditis vasculitis. These events result from aberrant activation T cells self-antigens within myocardium or vascular endothelium. Second, disruption homeostasis ICIs lead autoimmune-mediated inflammation tissues, manifesting dysfunction heart failure, arrhythmias, pericarditis. Furthermore, upregulation inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, interleukin-17 contributes endothelial dysfunction, plaque destabilization, thrombosis, exacerbating risk on long term. Understanding intricate side effects induced crucial for optimizing patient care ensure safe effective integration immunotherapy into broader range treatment protocols. The implications these underscore importance vigilant monitoring early detection in patients receiving Future key pathological mediators biomarkers may aid prompt diagnosis cardiotoxicity will allow timely interventions.
Язык: Английский
Процитировано
13
World Journal of Transplantation, Год журнала: 2024, Номер 15(1)
Опубликована: Ноя. 26, 2024
The endothelium modulates vascular homeostasis owing to a variety of vasoconstrictors and vasodilators. Endothelial dysfunction (ED), characterized by impaired vasodilation, inflammation, thrombosis, triggers future cardiovascular (CV) diseases. Chronic kidney disease, state chronic inflammation caused oxidative stress, metabolic abnormalities, infection, uremic toxins damages the endothelium. ED is also associated with decline in estimated glomerular filtration rate. After transplantation, endothelial functions undergo immediate but partial restoration, promising graft longevity enhanced CV health. However, anticipated outcomes do not happen due various transplant-related unrelated risk factors for ED, culminating poor health survival. transplant recipients an under-recognized poorly studied entity. diseases are leading cause death among candidates functioning grafts. contributes pathogenesis many Various biomarkers vasoreactivity tests available study functions. With increasing number transplants happening every year, improved rejection rates availability effective immunosuppressants, focus has now shifted protection prevention, early recognition, treatment
Язык: Английский
Процитировано
7
Frontiers in Pharmacology, Год журнала: 2025, Номер 16
Опубликована: Фев. 28, 2025
Ischemic cardiomyopathy (ICM) is a special type or end stage of coronary heart disease other irreversible ischemic myocardial injury. Inflammatory damage to vessels crucial factor in causing stenosis occlusion arteries, resulting ischemia and hypoxia, but it also an aspect cardioprotection that often overlooked. This review discusses the mechanisms vascular injury during ICM, which inflammation oxidative stress interact trigger cell death as cause microvascular Imbalances endoplasmic reticulum function mitochondrial quality control are important potential drivers stress. In addition, many studies have confirmed therapeutic effects Chinese herbal medicines their natural monomeric components on injuries. Their protection well role combating improvements endothelial attenuating summarized, with perspective provide reference for pathologic understanding, drug research, clinical application ICM-associated
Язык: Английский
Процитировано
1
Basic Research in Cardiology, Год журнала: 2024, Номер unknown
Опубликована: Сен. 30, 2024
Язык: Английский
Процитировано
6
Basic Research in Cardiology, Год журнала: 2024, Номер unknown
Опубликована: Июль 22, 2024
Abstract Immune checkpoint inhibitor (ICI) therapy represents a ground-breaking paradigm in cancer treatment, harnessing the immune system to combat malignancies by targeting checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1). The use of ICI generates distinctive immune-related adverse events (irAEs) including cardiovascular toxicity, necessitating targeted research efforts. This comprehensive review explores preclinical models dedicated ICI-mediated complications myocarditis. Tailored myocardial toxicities highlight key role CD8 + T cells, emphasizing profound impact on maintaining cardiac integrity. Cytokines macrophages were identified possible driving factors disease progression, at same time, initial data antigens responsible are emerging. implications contributing thoracic radiation, autoimmune disorder, presence itself increasingly understood. Besides myocarditis, mouse unveiled an accelerated progression atherosclerosis, adding another layer for thorough understanding diverse processes involving signalling. aims discuss current cardiotoxicity their potential improving enhanced risk assessment diagnostics, offering targets innovative cardioprotective strategies. Lessons from can drive novel approaches research, extending insights areas infarction heart failure.
Язык: Английский
Процитировано
5
Basic Research in Cardiology, Год журнала: 2024, Номер unknown
Опубликована: Сен. 9, 2024
Язык: Английский
Процитировано
5
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(18), С. 10177 - 10177
Опубликована: Сен. 22, 2024
Certain anticancer therapies inevitably increase the risk of cardiovascular events, now second leading cause death among cancer patients. This underscores critical need for developing effective drugs or regimens protection. Statins possess properties such as antioxidative stress, anti-inflammatory effects, antifibrotic activity, endothelial protection, and immune modulation. These pathological processes are central to cardiotoxicity associated with treatment. There is prospective clinical evidence confirming protective role statins in chemotherapy-induced cardiotoxicity. Numerous preclinical studies have demonstrated that can ameliorate heart damage caused by radiotherapy, although scarce. In animal models trastuzumab-induced cardiomyopathy, provide protection through anti-inflammatory, antioxidant, mechanisms. cell models, mitigate inflammation, damage, cardiac injury induced checkpoint inhibitors. Chimeric antigen receptor (CAR)-T therapy-induced effector cell-associated neurotoxicity syndrome uncontrolled inflammation activation. Due their immunomodulatory been used manage CAR-T a trial. However, direct proving still lacking. review summarizes possible mechanisms potential which may reduce related damage. We also discuss current status research on effect treatment-related disease directions future research. Additionally, we propose further using prevention
Язык: Английский
Процитировано
5
Basic Research in Cardiology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 8, 2024
Despite accumulating data on underlying mechanisms, the influence of sex and prevalent cardio-metabolic co-morbidities manifestation severity immune checkpoint inhibitor (ICI)-induced cardiotoxicity has not been well defined. To elucidate whether affect ICI-induced cardiotoxicity, we randomized 17-month-old male female mice to receive control diet (CON) or high-fat (HFD) + L-NAME-a well-established mouse model co-morbidities-for 17 weeks (n = 5-7), evaluated markers T-cell function in spleen. As expected, HFD L-NAME significantly increased body- heart weight, serum cholesterol levels, caused no systolic dysfunction, however, led diastolic cardiomyocyte hypertrophy, fibrosis only males compared corresponding CON. Western blot analyses splenic protein levels showed differential expression depending co-morbidities, suggesting exhaustion both sexes L-NAME, but more pronounced males. In a sub-study with similar setup, tested cardiotoxic manifestations ICI by treating anti-PD-1 monoclonal antibody (ICI) for last 2 administration 5-7). After treatment, cardiac functions decreased CON, groups baseline (before administration). conclusion, this exploratory study using aged mice, describe first time that ICI-related dysfunction is diminished when obesity hypercholesterolemia are present, possibly due obesity-related exhaustion.
Язык: Английский
Процитировано
3
Life, Год журнала: 2025, Номер 15(3), С. 471 - 471
Опубликована: Март 15, 2025
The increasing efficacy of cancer therapies has significantly improved survival rates, but it also highlighted the prevalence cancer-therapy-related cardiac dysfunction (CTRCD). This review provides a comprehensive overview identification, monitoring, and management CTRCD, condition resulting from several treatments, such as anthracyclines, HER2-targeted therapies, target radiotherapy. paper includes discussion mechanisms CTRCD associated with various treatments. Early detection through serum biomarkers advanced imaging techniques is crucial for effective monitoring risk stratification. Preventive strategies include pharmacological interventions ACE inhibitors/angiotensin receptor blockers, beta-blockers, statins. Additionally, novel agents like sacubitril/valsartan, sodium-glucose co-transporter type 2 inhibitors, vericiguat show promise in managing left ventricular dysfunction. Lifestyle modifications, including structured exercise programs optimized nutritional strategies, further contribute to cardioprotection. latest treatments both asymptomatic symptomatic across its stages are discussed. Emerging technologies, genomics, artificial intelligence, biomarkers, gene therapy, paving way personalized approaches prevention treatment. These advancements hold great improving long-term outcomes patients by minimizing cardiovascular complications.
Язык: Английский
Процитировано
0
Immunotherapy, Год журнала: 2025, Номер unknown, С. 1 - 9
Опубликована: Май 16, 2025
To evaluate whether immune checkpoint inhibitor (ICI) therapy is associated with a higher incidence of hypertension (HTN) among cancer patients compared to those not treated ICIs. This retrospective cohort study utilized data from the TriNetX Research Network, global database de-identified electronic health records. Adult (≥18 years) lung, breast, colon, kidney, or skin were categorized based on ICI treatment. Patients preexisting excluded. Propensity score matching (1:1) demographics and comorbidities yielded two balanced cohorts 24,956 each. The primary outcome was within one year diagnosis. significantly in group (13.2%) non-ICI (9.7%). risk ratio 1.356 (95% CI: 1.271-1.446), odds 1.410 1.311-1.516), both p < 0.001. Kaplan-Meier analysis showed lower hypertension-free survival (log-rank 0.001; HR = 1.071). an increased developing hypertension. These findings support need for routine cardiovascular monitoring receiving
Язык: Английский
Процитировано
0